{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:13:06Z","timestamp":1793459586040,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007464","name":"Torsten S\u00f6derbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007464","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jpsychires.2022.12.003","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T23:31:59Z","timestamp":1671492719000},"page":"319-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: Two open-label pilot studies on treatment-resistant patients"],"prefix":"10.1016","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-6075","authenticated-orcid":false,"given":"Susanne","family":"Bejerot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Sigra Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4258-5348","authenticated-orcid":false,"given":"Elisabet","family":"Welin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0547-4398","authenticated-orcid":false,"given":"Ulrika","family":"Hyl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6726-7787","authenticated-orcid":false,"given":"Mats B.","family":"Humble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2022.12.003_bib1","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s10803-011-1191-3","article-title":"The Swedish version of the Ritvo autism and asperger diagnostic scale: revised (RAADS-R). A validation study of a rating scale for adults","volume":"41","author":"Andersen","year":"2011","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","year":"1994"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib3","series-title":"Clinician-rated Dimensions of Psychosis Symptom Severity. Diagnostic and Statistical Manual of Mental Disorders. fifth ed. DSM-5, Arlington VA","first-page":"743","year":"2013"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib4","series-title":"Clinician-rated Severity of Autism Spectrum and Social Communication Disorder. Diagnostic and Statistical Manual of Mental Disorders","first-page":"52","year":"2013"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jamapsychiatry.2017.1567","article-title":"Inflammation in the neurocircuitry of obsessive-compulsive disorder","volume":"74","author":"Attwells","year":"2017","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3109\/08039488.2014.884631","article-title":"The Brief Obsessive-Compulsive Scale (BOCS): a self-report scale for OCD and obsessive-compulsive related disorders","volume":"68","author":"Bejerot","year":"2014","journal-title":"Nord. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13256-018-1929-z","article-title":"Neuromyelitis optica spectrum disorder with increased aquaporin-4 microparticles prior to autoantibodies in cerebrospinal fluid: a case report","volume":"13","author":"Bejerot","year":"2019","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.797165","article-title":"Joint hypermobility in paediatric acute-onset neuropsychiatric syndrome-A preliminary case-control study","volume":"12","author":"Bejerot","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10067-020-04996-7","article-title":"Effects of rituximab therapy on B cell differentiation and depletion","volume":"39","author":"Bergantini","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0447.1996.tb09814.x","article-title":"Catatonia. I. Rating scale and standardized examination","volume":"93","author":"Bush","year":"1996","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bbi.2012.08.005","article-title":"Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations?","volume":"26","author":"Busse","year":"2012","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.12.003_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neubiorev.2021.03.004","article-title":"Impaired regulatory T cell control of astroglial overdrive and microglial pruning in schizophrenia","volume":"125","author":"Corsi-Zuelli","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib15","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1007\/s12035-018-1409-x","article-title":"Immune aberrations in obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"56","author":"Cosco","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.jpsychires.2022.12.003_bib16","doi-asserted-by":"crossref","first-page":"e768","DOI":"10.1038\/tp.2016.34","article-title":"Exon-focused genome-wide association study of obsessive-compulsive disorder and shared polygenic risk with schizophrenia","volume":"6","author":"Costas","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib17","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.3390\/jcm10173849","article-title":"The role of cytokines in the pathogenesis of schizophrenia","volume":"10","author":"Dawidowski","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib18","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2215-0366(18)30345-6","article-title":"The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Deakin","year":"2018","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s11481-015-9626-9","article-title":"Adaptive immunity in schizophrenia: functional implications of T cells in the etiology, course and treatment","volume":"10","author":"Debnath","year":"2015","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib20","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2174\/1570159X16666180813155017","article-title":"Psychopharmacological treatment of obsessive-compulsive disorder (OCD)","volume":"17","author":"Del Casale","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England","volume":"27","author":"Devlin","year":"2018","journal-title":"Health Econ."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib22","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jpsychires.2022.12.003_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41398-021-01700-4","article-title":"Immunological causes of obsessive-compulsive disorder: is it time for the concept of an \"autoimmune OCD\" subtype?","volume":"12","author":"Endres","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/pcn.12430","article-title":"Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: a placebo-controlled, double-blind, randomized trial","volume":"70","author":"Esalatmanesh","year":"2016","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1352458517690824","article-title":"The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis","volume":"23","author":"Feys","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/imm.13198","article-title":"The role of B cells in the immunopathogenesis of multiple sclerosis","volume":"160","author":"Gharibi","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib27","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/npp.2017.258","article-title":"A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia","volume":"43","author":"Girgis","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib28","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib29","first-page":"861","article-title":"Assessment of severity and change in obsessive compulsive disorder","volume":"15","author":"Goodman","year":"1992","journal-title":"Psychiatr. Clin."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib31","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib32","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2017.2200","article-title":"Obsessive-compulsive disorder: advances in diagnosis and treatment","volume":"317","author":"Hirschtritt","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/ajp.156.2.317","article-title":"B lymphocyte antigen D8\/17 and repetitive behaviors in autism","volume":"156","author":"Hollander","year":"1999","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib34","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1002\/mpr.1567","article-title":"Adult executive functioning inventory (ADEXI): validity, reliability, and relations to ADHD","volume":"27","author":"Holst","year":"2018","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2022.113743","article-title":"Skewing of the antibody repertoire in cerebrospinal fluid B cells from healthy controls and patients with schizophrenia","volume":"422","author":"Husain-Krautter","year":"2022","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib37","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00213-015-3975-1","article-title":"Is there a role for immune-to-brain communication in schizophrenia?","volume":"233","author":"Khandaker","year":"2016","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment","volume":"2","author":"Khandaker","year":"2015","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib39","series-title":"The Personality Inventory for DSM-5 (PID-5) Brief Form. Diagnostic and Statistical Manual of Mental Disorders","author":"Krueger","year":"2013"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0149-7189(79)90094-6","article-title":"Assessment of client\/patient satisfaction: development of a general scale","volume":"2","author":"Larsen","year":"1979","journal-title":"Eval. Progr. Plann."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgab012","article-title":"Immune signatures of treatment-resistant schizophrenia: a FondaMental academic centers of expertise for schizophrenia (FACE-SZ) study","volume":"2","author":"Leboyer","year":"2021","journal-title":"Schizophr. Bull. Open"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/cap.2019.0041","article-title":"N-Acetylcysteine for pediatric Obsessive-Compulsive Disorder: a small pilot study","volume":"30","author":"Li","year":"2020","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib44","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/16506073.2016.1143526","article-title":"The brunnsviken brief quality of life scale (BBQ): development and psychometric evaluation","volume":"45","author":"Lindner","year":"2016","journal-title":"Cognit. Behav. Ther."},{"issue":"Suppl. 44","key":"10.1016\/j.jpsychires.2022.12.003_bib45","first-page":"5","article-title":"Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord","volume":"55","author":"Lindstr\u00f6m","year":"2001","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjo.2019.30","article-title":"Retrospective parental assessment of childhood neurodevelopmental problems: the use of the Five to Fifteen questionnaire in adults","volume":"5","author":"Lugneg\u00e5rd","year":"2019","journal-title":"BJPsych. Open."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib47","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.focus.20200015","article-title":"Evaluating the hypothesis that schizophrenia is an inflammatory disorder","volume":"18","author":"Miller","year":"2020","journal-title":"Focus"},{"issue":"3","key":"10.1016\/j.jpsychires.2022.12.003_bib48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jpsychires.2005.04.003","article-title":"Subtyping obsessive-compulsive disorder: clinical and immunological findings in child and adult onset","volume":"40","author":"Morer","year":"2006","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib49","first-page":"323","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104408","article-title":"Emerging role of innate B1 cells in the pathophysiology of autoimmune and neuroimmune diseases: association with inflammation, oxidative and nitrosative stress and autoimmune responses","volume":"148","author":"Morris","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib51","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sby024","article-title":"Inflammation in Schizophrenia: pathogenetic aspects and therapeutic considerations","volume":"44","author":"M\u00fcller","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib52","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/ajp.154.3.402","article-title":"B lymphocyte antigen D8\/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome?","volume":"154","author":"Murphy","year":"1997","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.schres.2021.01.024","article-title":"The effect of prednisolone on symptom severity in schizophrenia: a placebo-controlled, randomized controlled trial","volume":"230","author":"Nasib","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib55","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/schbul\/sbp124","article-title":"Should the PANSS be rescaled?","volume":"36","author":"Obermeier","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib56","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamapsychiatry.2017.0995","article-title":"Association of streptococcal throat infection with mental disorders: testing key aspects of the PANDAS hypothesis in a nationwide study","volume":"74","author":"Orlovska","year":"2017","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib57","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/jclinpath-2019-206235","article-title":"Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID)","volume":"73","author":"Ponsford","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib58","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.comppsych.2011.08.009","article-title":"Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications","volume":"53","author":"Poyurovsky","year":"2012","journal-title":"Compr. Psychol."},{"issue":"S1","key":"10.1016\/j.jpsychires.2022.12.003_bib59","first-page":"S222","article-title":"Celecoxib add-on therapy does not have beneficial antipsychotic effects over risperidone alone in schizophrenia","volume":"29","author":"Rappard","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib60","author":"Rituxan side-effect drug list"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib61","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s10803-010-1133-5","article-title":"The ritvo autism asperger diagnostic scale-revised (RAADS-R): a scale to assist the diagnosis of autism spectrum disorder in adults: an international validation study","volume":"41","author":"Ritvo","year":"2011","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib62","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.bbi.2019.07.022","article-title":"Altered frequencies of Th17 and Treg cells in children and adolescents with obsessive-compulsive disorder","volume":"81","author":"Rodr\u00edguez","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib63","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib64","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bbi.2020.04.021","article-title":"Increased densities of T and B lymphocytes indicate neuroinflammation in subgroups of schizophrenia and mood disorder patients","volume":"88","author":"Schlaaff","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib65","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0035-1549929","article-title":"Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: a double-blind, placebo-controlled, randomized trial","volume":"48","author":"Shalbafan","year":"2015","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl. 20","key":"10.1016\/j.jpsychires.2022.12.003_bib66","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib67","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1192\/bjp.2021.61","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis","volume":"220","author":"Siskind","year":"2022","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib68","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/schbul\/sbab010","article-title":"Simvastatin augmentation for patients with early-phase schizophrenia-spectrum disorders: a double-blind, randomized placebo-controlled trial","volume":"47","author":"Sommer","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib69","article-title":"Evolution of anti-B cell therapeutics in autoimmune neurological diseases","volume":"18","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics. Feb"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib70","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00406-010-0098-x","article-title":"Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity","volume":"260","author":"Steiner","year":"2010","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib71","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.comppsych.2015.08.007","article-title":"Defining clinical severity in adults with obsessive-compulsive disorder","volume":"63","author":"Storch","year":"2015","journal-title":"Compr. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib72","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jpsychires.2021.03.035","article-title":"Reduced T cell immunity in unmedicated, comorbidity-free obsessive-compulsive disorder: an immunophenotyping study","volume":"137","author":"Subbanna","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib73","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4172\/2161-0665.1000113","article-title":"From research subgroup to clinical syndrome: modifying the PANDAS criteria to describe PANS (pediatric acute-onset neuropsychiatric syndrome)","volume":"2","author":"Swedo","year":"2012","journal-title":"Pediatr. Therapeut."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib74","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/HRP.0000000000000326","article-title":"Brick by brick: building a transdiagnostic understanding of inflammation in psychiatry","volume":"30","author":"Thylur","year":"2022","journal-title":"Harv. Rev. Psychiatr."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib75","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbi.2019.06.043","article-title":"B-cells and schizophrenia: a promising link or a finding lost in translation?","volume":"81","author":"van Mierlo","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijporl.2015.11.020","article-title":"Characterization of B-Cells in tonsils of patients diagnosed with pediatric autoimmune neuropsychiatric disorder associated streptococcus","volume":"80","author":"Walls","year":"2016","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib77","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jneuroim.2010.09.012","article-title":"Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis","volume":"231","author":"Wandinger","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib79","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/schbul\/sbaa198","article-title":"Adjunctive aspirin vs placebo in patients with schizophrenia: results of two randomized controlled trials","volume":"47","author":"Weiser","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib80","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/08916934.2017.1281914","article-title":"B cells in multiple sclerosis","volume":"50","author":"Wekerle","year":"2017","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jpsychires.2022.12.003_bib81","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2022.12.003_bib82","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1192\/bjp.169.4.468","article-title":"Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators","volume":"169","author":"Zohar","year":"1996","journal-title":"Br. J. Psychol."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395622006719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395622006719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:36:41Z","timestamp":1758368201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395622006719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":79,"alternative-id":["S0022395622006719"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2022.12.003","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: Two open-label pilot studies on treatment-resistant patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2022.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}